Melanoma-associated antigen D2 (MAGED2)

Melanoma-associated antigen D2 (MAGED2) is a member of the MAGE cancer-testis antigen family, encoded on the X chromosome (Xp11.2), and is widely expressed at the protein level with cytoplasmic and nuclear localization[3]. MAGED2 regulates the cell cycle, DNA damage response, cell proliferation, apoptosis, and cell migration. In cancer, particularly triple-negative breast cancer, it acts as a cancer-promoting factor by activating the PI3K–AKT signaling pathway and promoting metastasis. MAGED2 also interacts with Hsp70, protecting it from proteasomal degradation, which supports cancer cell viability and spread. Germline mutations in MAGED2 cause transient antenatal Bartter syndrome, implicating it in renal salt reabsorption through effects on SLC12A1 and SLC12A3 cotransporters[2]. MAGED2 is considered a potential oncological therapeutic target, with increased expression linked to poor prognosis in breast cancer and other malignancies[1][2].

Other names

MAGE family member D2BCG1BCG-1JCL-111B6HCA10MAGEDMGC8386Breast cancer-associated gene 1 proteinHepatocellular carcinoma-associated protein JCL-1MAGE-D2 antigenhepatocellular carcinoma associated proteinbreast cancer associated gene 1melanoma antigen family D, 2BARTS5

Blocking MAGE-D2 impairs proliferation and metastasis, at least partly by disrupting its protection of Hsp70 from proteasomal degradation, and by attenuating PI3K–AKT signaling pathway activation[1].